Wellgem Biopharma - Company finances
|
EUR
|
2021
From: 2021-12-13
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 139,741 | 298,561 | 137,620 | 243,300 |
| Profit before tax | - | - | -309,729 | -419,214 | -1,041,912 |
| Net profit | -5,498 | -123,360 | -309,729 | -419,214 | -1,041,912 |
| Equity | 94,502 | -28,858 | -332,427 | -751,641 | 1,206,448 |
| Liabilities | 27,443 | 1,531,301 | 1,999,702 | 7,251,641 | 8,498,131 |
| Non-current assets | 21,945 | 1,416,081 | 1,480,036 | 4,223,088 | 9,413,965 |
| Current assets | 100,000 | 85,962 | 185,537 | 2,375,290 | 251,577 |
| Total assets | 121,945 | 1,502,043 | 1,665,573 | 6,598,378 | 9,665,542 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 53,503 | 46,326 | - |
| Social insurance contributions | - | - | 87,841 | 139,473 | 250,479 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | +113.7% | -53.9% | +76.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -4.5% | -8.2% | -18.6% | -6.4% | -10.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -5.8% | - | - | - | -86.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -88.3% | -103.7% | -304.6% | -428.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | -103.7% | -304.6% | -428.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | - | - | - | 7.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 47,911 | 44,784 | 14,115 | 11,868 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Wellgem Biopharma - Social security debts
The amount of overdue SODRA debt for the company Wellgem Biopharma as of the last working day is: 12,139 €
| From | To | Debt, € |
|---|---|---|
| 2026-10-07 | 2026-10-09 | 12139.47 |
| 2026-10-03 | 2026-10-05 | 12139.47 |
| 2026-09-26 | 2026-09-28 | 12139.47 |
| 2026-09-20 | 2026-09-21 | 12139.47 |
| 2026-09-10 | 2026-09-17 | 12139.47 |
| 2026-09-05 | 2026-09-09 | 12065.07 |
| 2026-08-23 | 2026-09-02 | 12065.07 |
| 2026-08-18 | 2026-08-19 | 12065.07 |
| 2026-08-04 | 2026-08-17 | 12009.33 |
| 2026-07-26 | 2026-08-03 | 12498.99 |
| 2026-07-23 | 2026-07-25 | 12083.73 |
| 2026-07-21 | 2026-07-22 | 12009.33 |
| 2026-07-19 | 2026-07-20 | 12498.99 |
| 2026-07-16 | 2026-07-17 | 12498.99 |
| 2026-07-08 | 2026-07-15 | 6119.34 |
| 2026-06-30 | 2026-07-07 | 6124.32 |
| 2026-06-11 | 2026-06-29 | 315.45 |
| 2026-05-17 | 2026-06-08 | 315.45 |
| 2026-04-27 | 2026-04-28 | 3240.63 |
| 2026-04-26 | 2026-04-26 | 3073.80 |
| 2026-04-24 | 2026-04-25 | 3240.73 |
| 2026-04-23 | 2026-04-23 | 3073.80 |
| 2026-04-20 | 2026-04-22 | 8344.57 |
| 2026-03-27 | 2026-03-27 | 18794.12 |
| 2026-03-17 | 2026-03-25 | 18794.12 |
| 2026-02-27 | 2026-03-11 | 18978.70 |
| 2026-02-18 | 2026-02-26 | 19199.14 |
| 2025-05-04 | 2025-05-13 | 8.90 |
| 2025-04-24 | 2025-04-29 | 8.90 |
| 2025-02-18 | 2025-03-04 | 4.19 |
| 2025-02-12 | 2025-02-13 | 4.19 |
| 2025-01-16 | 2025-01-16 | 16488.64 |
| 2024-07-24 | 2024-08-12 | 18.51 |
| 2024-06-18 | 2024-06-24 | 800.51 |
| 2024-05-16 | 2024-05-22 | 7176.63 |
| 2022-01-18 | 2022-01-27 | 6.38 |
Wellgem Biopharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Wellgem Biopharma, UAB (code 305953703) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In the latest financial year, 2025, revenue increased by 76.8% year on year to €243.3K, after €137.6K in 2024, but remained below €298.6K in 2023. Profitability weakened materially: net loss widened to €1.04M in 2025 from €419.2K in 2024 and €309.7K in 2023, showing that expenses continued to outpace sales. The latest loss was much larger than revenue, resulting in a very weak margin. At year-end 2025, total assets were €9.67M, supported mainly by long-term assets of €9.41M; short-term assets were €251.6K. Equity turned positive at €1.21M, while liabilities reached €8.50M, giving an equity ratio of 12.5% and debt-to-equity of 7.04. Return on equity was -86.4%, return on assets -10.8%, and asset turnover 0.03x. Revenue per employee was €12.2K, while profit per employee was -€52.1K.